

### Statement about Free Writing Prospectus



The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this presentation relates. This free writing prospectus relates to the proposed public offering of Series A Preferred Stock of Medical Transcription Billing, Corp. (the "Company"), which is being registered on a Registration Statement on Form S-1 (the "Registration Statement"), Commission File No. 333-214863. This free writing prospectus should be read together with the preliminary prospectus included in that Registration Statement (including the risk factors described therein), which can be accessed through the following link:

https://www.sec.gov/Archives/edgar/data/1582982/000149315216015825/forms-1a.htm

Before you invest, you should read the prospectus in that Registration Statement and the other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the preliminary prospectus if you request it by calling Bill Korn (732) 873-5133 x 133 or emailing bkorn@MTBC.com.

#### **Forward-Looking Statements**



This presentation contains forward-looking statements within the meaning of the federal securities laws. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as "anticipate", "believe", "continue", "could", "estimate", "expect", "goals", "intend", "likely", "may", "plan", "potential", "predict", "project", "will" or the negative of these terms or other similar terms and phrases.

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this presentation include, without limitation, statements reflecting management's expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, increased sales and marketing expenses, and the expected results from the integration of our acquisitions.

Forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. These factors

- our ability to manage our growth, including acquiring, partnering with, and effectively integrating the recent acquisitions into our infrastructure; our ability to retain our customers and revenue levels, including effectively migrating and keeping new customers acquired through business acquisitions and maintaining or growing the revenue levels of our new and existing customers;
- our ability to attract and retain key officers and employees, including Mahmud Haq and personnel critical to the transitioning and integration of our newly acquired businesses;
- our ability to raise capital and obtain and maintain financing on acceptable terms;
- our ability to compete with other companies developing products and selling services competitive with ours, and who may have greater resources and name recognition than we have;
- our ability to maintain operations in Pakistan, Poland, Sri Lanka and India in a manner that continues to enable us to offer competitively priced products and services:
- our ability to keep and increase market acceptance of our products and services;
- our ability to keep pace with a rapidly changing healthcare industry;
- our ability to consistently achieve and maintain compliance with a myriad of Federal, State, foreign, local, payor and industry requirements, regulations, rules and laws;
- our ability to protect and enforce intellectual property rights;
- our ability to maintain and protect the privacy of customer and patient information;
- our ability to meet continuing listing standards on the Nasdaq Capital Market, including its requirement that the minimum bid price for our common stock be at or above \$1.00; and
- our ability to maintain compliance with key covenants in our debt facilities with Opus Bank and any other future debt facilities.

Although we believe that the expectations reflected in the forward-looking statements contained in this presentation are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

The statements in this presentation are made as of the date of this presentation, and the Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.


## **Transaction Overview**




Issuer	Medical Transcription Billing, Corp.			
Exchange: Symbol	NASDAQ Capital Market: MTBCP			
Shares Offered	11% Series A Cumulative Redeemable Perpetual Preferred Stock (1)			
Dividends	Payable on the 15 <sup>th</sup> day of each month			
Par Value	\$25.00 per share			
Offering Size	\$10,000,000			
Over-Allotment Option	15%			
Use of Proceeds	<ul> <li>\$5,000,000 for remainder of MediGain acquisition purchase price</li> <li>Future acquisitions and organic growth</li> <li>General corporate purposes and additional working capital</li> </ul>			
Bookrunners	Chardan. Boenning & Scattergood			
Co-Manager	Joseph Gunnar & Co.			

(1) The shares are redeemable after November 4, 2020 at par value.







## **Experienced Leadership Team**





Mahmud Hag

- Former CEO of Compass International Services Corporation (Nasdaq: CMPS). Completed 14 acquisitions in 18 months during 1998 - 1999, growing revenue from \$87 million at the time of IPO to a run rate of ~\$180 million at the time Compass was acquired by NCO Group, Inc. (Nasdaq: NCOG) for \$112 million of consideration to shareholders
- Held various senior executive positions at American Express Company (NYSE: AXP) for 12 years including Vice President of Global Risk Management
- B.S. in Aviation Management, Bridgewater State College (Massachusetts). M.B.A. in Finance, Clark University (Massachusetts)

CEO and Chairman of the Board



Stephen Snyder President and Director

- Joined MTBC in 2005. Formerly served as VP / General Counsel and Chief Operating Officer
- Attorney for 15 years with M&A and healthcare law experience
- Writings on healthcare industry, law and policy have been published by American Bar Association and various healthcare industry publications
- J.D. Rutgers School of Law Newark, senior editor of law journal



Bill Korn Chief Financial Officer

- Joined MTBC in 2013
- Former CFO of Antenna Software, Inc. from 2002 - 2012, where he completed 5 acquisitions and was a key contributor to growing the business at a CAGR of 87%
- Former executive at IBM (NYSE: IBM) for 10 years. He was part of the senior management team that created IBM's highly successful services strategy in the
- · A.B. in Economics magna cum laude, Harvard College. M.B.A. Harvard Business School

## **Distinguished Board of Directors**





 Former CFO of American Express Company (NYSE: AXP)

 Former CEO, Chairman and Vice Chairman of Shearson Lehman and Vice Chairman of Barclays Capital



 Board member of Pitney Bowes Inc. (NYSE: PBI), Intercontinental Hotels Group plc (LSE: IHG) and Provista Diagnostics, Inc.

 Former President of American Express Interactive Services and New Businesses Division

Howard Clark Jr.





 Former EVP and Director of E.F. Hutton & Company

 Former Head of Private Client

 Former Head of Private Client Division and Int'l Equity Capital Markets at Salomon Brothers




 President and CEO of the East-West Institute

 Former U.S. Ambassador to Pakistan and U.S. Deputy Chief of Mission to Poland

John Daly

**Cameron Munter** 


Management plus Board members own 53% of MTBC's common stock




















# **Dividend History**



Month	Declaration Date	Ex-Dividend Date	Record Date	Payment Date	Dividend per Share
February, 2017	11/14/2016	2/24/2017	2/28/2017	3/15/2017	\$0.2292
January, 2017	11/14/2016	1/27/2017	1/31/2017	2/15/2017	\$0.2292
December, 2016	11/14/2016	12/28/2016	12/31/2016	1/17/2017	\$0.2292
November, 2016	8/11/2016	11/28/2016	11/30/2016	12/15/2016	\$0.2292
October, 2016	8/11/2016	10/27/2016	10/31/2016	11/15/2016	\$0.2292
September, 2016	8/11/2016	9/28/2016	9/30/2016	10/17/2016	\$0.2292
August, 2016	5/17/2016	8/29/2016	8/31/2016	9/15/2016	\$0.2292
July, 2016	5/17/2016	7/27/2016	7/31/2016	8/15/2016	\$0.2292
June, 2016	5/17/2016	6/28/2016	6/30/2016	7/15/2016	\$0.2292
May, 2016	3/31/2016	5/26/2016	5/31/2016	6/15/2016	\$0.2292
April, 2016	3/22/2016	4/27/2016	4/30/2016	5/16/2016	\$0.2292
March, 2016	3/22/2016	3/29/2016	3/31/2016	4/15/2016	\$0.2292
February, 2016	11/10/2015	2/25/2016	2/29/2016	3/15/2016	\$0.2292
January, 2016	11/10/2015	1/27/2016	1/31/2016	2/16/2016	\$0.2292
December, 2015	11/10/2015	12/29/2015	12/31/2015	1/15/2016	\$0.2292
November, 2015	11/10/2015	11/25/2015	11/30/2015	12/15/2015	\$0.20625*

<sup>\*</sup> Represents a prorated amount for the period 11/4/2015 through 11/30/2015.

# **Balance Sheet Snapshot**



(\$ in millions)	December 31, September 30, 2016			
	2015 Actual	Actual	Pro Forma	After Financing
Cash	\$8.0	\$7.1	\$5.2	\$9.1
Accounts Receivable	2.2	2.1	4.3	4.3
Total Assets	\$26.7	\$24.8	\$31.1	\$35.0
Total Debt	\$8.0	\$9.9	\$14.9	\$9.9
Total Liabilities	11.8	13.7	20.0	15.0
Shareholders' Equity	\$14.9	\$11.1	\$11.1	\$20.0

#### NOTES

- 1) Pro Forma includes MediGain acquisition, which occurred on Oct. 3, 2016
- 2) After Financing includes sale of \$10 M of additional Series A Preferred Stock, less offering expenses
- 3) MTBC sold \$5.8 M Series A Preferred in Nov 2015 and an additional \$1.6 M in July 2016
- 4) \$9.9 million was drawn on MTBC's \$10 M credit facility with Opus Bank on Sept. 30, 2016
- 5) Pro Forma includes \$5 M of debt, the remaining portion of the MediGain acquisition price, due in January 2017

